Lab Manager | Run Your Lab Like a Business

BD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis

BD Rhapsody™ single cell analysis system launches for gene expression profiling, plans to expand for protein analysis

by Becton, Dickinson and Company
Register for free to listen to this article
Listen with Speechify

BD RhapsodyFRANKLIN LAKES, N.J., Sept. 12, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of BD Rhapsody, a platform for single cell analysis with the ability to detect rare molecules responsible for biological diversity that are often missed with whole transcriptome profiling.

Developed using the company’s patented unique molecular index (UMI) technology, BD Rhapsody is a complete system of reagents, instruments, and software for targeted gene expression analysis of tens of thousands of individual cells. The product was previously in limited commercial release under the name Resolve. BD will offer both application-specific targeted panels and enable customers to design their own custom, targeted panels.

“Early access users have been enthusiastic about our targeted assay solution and its superior performance compared to whole transcriptome profiling,” said Stephen Gunstream, vice president of Genomics for BD. “These same users have also experienced considerable sequencing cost savings from this technology.”

The BD Rhapsody platform assay offering will be rapidly expanded over the next 12 months. Shortly after launch, customers will be able to multiplex many samples in one run with the BD single-cell multiplexing kit, significantly increasing sample throughput while maintaining the low doublet rate. The platform is also being expanded beyond RNA expression to include protein detection, leveraging BD’s extensive antibody portfolio with BD AbSeq assays for protein expression.

“Initial data generated looks extremely positive and we believe true understanding of complex diseases will come with the ability to interrogate both protein and RNA in single cells simultaneously,” Gunstream added.

BD has initiated early access for AbSeq protein detection on the BD Rhapsody system and expects commercial availability in the first half of 2018. The BD Rhapsody system and AbSeq assays will be showcased at this year’s AGBT Precision Health and ASHG conferences.

These new products build on BD’s 40-year history of providing solutions for single cells using flow cytometry. With the BD Rhapsody system, researchers are able to easily discover both the gene expression and protein markers that more completely identify their cell population of interest.

Join BD at the AGBT meeting on Friday, Sept. 15 from 6:30 to 8:30 p.m. or on Saturday, Sept. 16 from 12:45 to 1 p.m. in the Camelback Ballroom for the workshop, BD Rhapsody system and AbSeq: Simultaneous RNA and protein analysis on tens of thousands of single cells.

More information on the BD Rhapsody system and the new BD single-cell multiplexing assays is available at

The BD Rhapsody system is for research use only and not for diagnostic or therapeutic use. For more information, contact BD at +1 650.665.2400.